BREAKING NEWS

Israel's MediWound signs $112m. deal in US for burn treatment

By REUTERS

SEPTEMBER 30, 2015 15:23

Israel-based MediWound has signed a five-year, $112 million contract with the US authority that handles public health medical emergencies to further develop and buy the company's drug treatment for severe burns.

Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research and Development Authority would raise preparedness for mass-casualty incidents.

The US body would also help MediWound get approval for its drug NexoBrid, a topical treatment that removes damaged tissue, from the Food and Drug Administration, Clal said.

Gallant addresses haredi enlistment to IDF in talk with soldiers

By JERUSALEM POST STAFF

11/05/2024 06:23 PM

Rocket sirens sound in Nahariya, northern Israel

By JERUSALEM POST STAFF

11/05/2024 05:22 PM

Trump: Kamala will start WW3, get millions of Muslims killed

By JERUSALEM POST STAFF

11/05/2024 01:10 PM

Putin tells Western diplomats Russia is committed to cooperation

By REUTERS

11/05/2024 01:08 PM